Nefecon
Phase 3Small molecule
Nefecon is one of 5 small molecule programs targeting IgA Nephropathy (IgAN). It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Iga Nephropathy (igan)
#DrugCompanyPhaseTrials
1Vanrafia
NovartisApproved
TRUTAKNA
VVera Therapeutics, Inc.
Phase 2
Nefecon
CCalliditas Therapeutics AB
Phase 3
SGB-9768
SSuzhou Sanegene Bio Inc.
Phase 2
Universal STAR-T Cell
DDaishi Tian
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
IgA Nephropathy2 trials
Nephropathy2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nefecon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCalliditas Therapeutics AB